Background Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3,
fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, RET, and …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
mortality worldwide. In the last few decades, there has been a marked increase in …

Background & Aims Sorafenib, an oral multikinase inhibitor, significantly prolonged overall
survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in …

Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein
kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a …

The present study aimed to examine the impact of sarcopenia, defined as low muscle mass
on computed tomography (CT), prior to sorafenib therapy on the clinical outcomes of …

Advanced stage hepatocellular carcinoma (HCC) is a category of disease defined by
radiological, clinical and hepatic function parameters, comprehending a wide range of …

Hepatocellular carcinoma (HCC) is one of the male-dominant liver diseases with poor
prognosis, although treatments for HCC have been progressing in the past decades …

Diffusion-weighted imaging (DWI) of the liver can be performed using most commercially
available machines and is currently accepted in routine sequence. This sequence has some …

The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with
advanced hepatocellular carcinoma (HCC). We previously reported that fibroblast growth …

Simple Summary Hepatocellular carcinoma (HCC) is a major cause of cancer-related death
worldwide. As the complex genetic landscape of HCC is considered to compromise the …